Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 5;16(6):1089-1097.
doi: 10.1021/acsmedchemlett.5c00121. eCollection 2025 Jun 12.

Salt-Tolerant, Protease-Stable and Non-Resistance Developing Cationic AMPs for Combatting Planktonic MRSA and its Biofilms

Maitery Yadav  1 , Tanisha Singh  1 , Harsh Vikram Singh  2 , Rajkumar P Thummer  2 , Sunanda Chatterjee  1
Affiliations

Salt-Tolerant, Protease-Stable and Non-Resistance Developing Cationic AMPs for Combatting Planktonic MRSA and its Biofilms

Maitery Yadav et al. ACS Med Chem Lett. .

Abstract

The global antimicrobial resistance crisis has stimulated the development of innovative therapeutics. Methicillin-resistant Staphylococcus aureus (MRSA), a critical pathogen responsible for skin and soft tissue infections. MRSA biofilms exhibit greater resistance to antibiotics compared to planktonic cells. Antimicrobial peptides (AMPs) are potential alternatives but face challenges like high costs, salt sensitivity, toxicity, and protease degradability. This study developed highly potent, salt-tolerant, nontoxic, and proteolytically stable membranolytic AMPs: d-WRL (composed of all d-amino acids) and W-(Dab)-L (incorporating 2,4-diaminobutyric acid), which effectively prevented planktonic MRSA, inhibited biofilm formation, and eradicated ∼80% of mature biofilms, outperforming vancomycin with faster killing kinetics. The biofilm eradication ability was attributed to their protease stability. The developed AMPs prevented resistance development in MRSA over 96 generations, unlike ciprofloxacin, and thus are critical additions to the limited arsenal of potential MRSA-targeting therapeutics.

Keywords: MRSA biofilms; antimicrobial peptides; membranolytic; nonresistance developing AMP; protease resistance.

PubMed Disclaimer

References

    1. Morris S., Cerceo E.. Trends, Epidemiology, and Management of Multi-Drug Resistant Gram-Negative Bacterial Infections in the Hospitalized Setting. Antibiotics. 2020;9(4):196. doi: 10.3390/antibiotics9040196. - DOI - PMC - PubMed
    1. Brezden A., Mohamed M. F., Nepal M., Harwood J. S., Kuriakose J., Seleem M. N., Chmielewski J.. Dual Targeting of Intracellular Pathogenic Bacteria with a Cleavable Conjugate of Kanamycin and an Antibacterial Cell-Penetrating Peptide. J. Am. Chem. Soc. 2016;138(34):10945–10949. doi: 10.1021/jacs.6b04831. - DOI - PMC - PubMed
    1. Gandra S., Tseng K. K., Arora A., Bhowmik B., Robinson M. L., Panigrahi B., Laxminarayan R., Klein E. Y.. The Mortality Burden of Multidrug-Resistant Pathogens in India: A Retrospective, Observational Study. Clinical Infectious Diseases. 2019;69(4):563–570. doi: 10.1093/cid/ciy955. - DOI - PMC - PubMed
    1. Mancuso G., Midiri A., Gerace E., Biondo C.. Bacterial Antibiotic Resistance: The Most Critical Pathogens. Pathogens. 2021;10(10):1310. doi: 10.3390/pathogens10101310. - DOI - PMC - PubMed
    1. Dweba C. C., Zishiri O., El Zowalaty M.. Methicillin-Resistant < em > Staphylococcus Aureus</Em>: Livestock-Associated, Antimicrobial, and Heavy Metal Resistance. Infect Drug Resist. 2018;11:2497–2509. doi: 10.2147/IDR.S175967. - DOI - PMC - PubMed

LinkOut - more resources